Safety and Efficacy of Topical NVC-422 Gel in Impetigo
A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo
Sponsor: International Dermatology Research, Inc.
A PHASE2 clinical study on Impetigo, this trial is completed. The trial is conducted by International Dermatology Research, Inc. and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Dermatology Research, Inc.
- NovaBay Pharmaceuticals, Inc.
- Novum Pharmaceutical Research Services
For direct contact, visit the study record on ClinicalTrials.gov .